MX2016010951A - Proteinas de fc multimericas. - Google Patents

Proteinas de fc multimericas.

Info

Publication number
MX2016010951A
MX2016010951A MX2016010951A MX2016010951A MX2016010951A MX 2016010951 A MX2016010951 A MX 2016010951A MX 2016010951 A MX2016010951 A MX 2016010951A MX 2016010951 A MX2016010951 A MX 2016010951A MX 2016010951 A MX2016010951 A MX 2016010951A
Authority
MX
Mexico
Prior art keywords
proteins
multimeric
relates
fusion proteins
tailpiece
Prior art date
Application number
MX2016010951A
Other languages
English (en)
Spanish (es)
Inventor
Paul Humphreys David
Jane Peters Shirley
John Smith Bryan
Fallah-Arani Farnaz
Anthony Griffin Robert
Edward Stephens Paul
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2016010951A publication Critical patent/MX2016010951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
MX2016010951A 2014-03-05 2015-03-05 Proteinas de fc multimericas. MX2016010951A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (1)

Publication Number Publication Date
MX2016010951A true MX2016010951A (es) 2016-11-29

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010951A MX2016010951A (es) 2014-03-05 2015-03-05 Proteinas de fc multimericas.

Country Status (15)

Country Link
US (1) US11352414B2 (enExample)
EP (1) EP3114143B1 (enExample)
JP (1) JP6851200B2 (enExample)
KR (1) KR20160130463A (enExample)
CN (1) CN106068274A (enExample)
AU (1) AU2015226100B2 (enExample)
BR (1) BR112016020368A2 (enExample)
CA (1) CA2939198A1 (enExample)
IL (1) IL247096A0 (enExample)
MX (1) MX2016010951A (enExample)
RU (1) RU2016139006A (enExample)
SG (1) SG11201606597QA (enExample)
TW (1) TW201619188A (enExample)
UY (1) UY36021A (enExample)
WO (1) WO2015132364A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
CN113501880A (zh) 2014-05-02 2021-10-15 动量制药公司 涉及工程化Fc构建体的组合物和方法
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
HUE053062T2 (hu) 2015-07-24 2021-06-28 Gliknik Inc Humán fehérjefragmensek fúziós fehérjéi szabályosan multimerizált, fokozott komplementkötésû immunglobulin FC kompozíciók elõállításához
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
US20190119377A1 (en) * 2016-01-27 2019-04-25 Csl Behring Recombinant Facility Ag Recombinant igg fc multimers
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
AU2017272111B2 (en) 2016-05-23 2024-05-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
US20190389941A1 (en) * 2016-07-22 2019-12-26 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
US11155574B2 (en) 2016-12-09 2021-10-26 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
SG10202107391YA (en) 2017-01-06 2021-08-30 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN113603781B (zh) * 2017-03-28 2022-09-02 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
JP7710827B2 (ja) * 2017-06-05 2025-07-22 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
CN112004550A (zh) * 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
AU2019235513A1 (en) * 2018-03-16 2020-10-08 Liverpool School Of Tropical Medicine Chimeric Fc receptor binding proteins and uses thereof
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
US12492231B2 (en) 2018-11-14 2025-12-09 Jn Biosciences Llc Multimeric hybrid Fc proteins for replacement of IVIG
EP4028415A1 (en) 2019-09-13 2022-07-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
CN114786721B (zh) * 2019-12-06 2025-10-17 康诺贝林伦瑙有限公司 Fc多聚体的稳定组合物
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体
CA3258884A1 (en) * 2022-06-10 2023-12-14 Research Development Foundation Modified FCRIIB Selective FC IGG1 Variants and Their Uses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
AU3369999A (en) 1998-04-02 1999-10-25 Genentech Inc. Antibody variants and fragments thereof
AU3655899A (en) 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN101987871A (zh) 2002-09-27 2011-03-23 赞科股份有限公司 优化的Fc变体及其产生方法
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CN103897063B (zh) * 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
AU2009224690B2 (en) * 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
EP2389192A4 (en) * 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
TWI588157B (zh) 2010-07-28 2017-06-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
CA2859785A1 (en) 2011-12-21 2013-06-27 Amgen Inc. Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
US9540442B2 (en) * 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
CN104718223A (zh) 2012-08-20 2015-06-17 格利克尼克股份有限公司 具有抗原结合和多价FCγ受体结合活性的分子
WO2014060712A1 (en) 2012-10-17 2014-04-24 Liverpool School Of Tropical Medicine Immunomodulatory proteins
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
US20170081406A1 (en) 2014-03-05 2017-03-23 Ucb Biopharma Sprl Multimeric fc proteins
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
CN113501880A (zh) 2014-05-02 2021-10-15 动量制药公司 涉及工程化Fc构建体的组合物和方法
AU2016227632A1 (en) 2015-03-05 2017-09-14 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Also Published As

Publication number Publication date
KR20160130463A (ko) 2016-11-11
WO2015132364A1 (en) 2015-09-11
CN106068274A (zh) 2016-11-02
AU2015226100B2 (en) 2020-05-07
UY36021A (es) 2015-09-30
JP2017512063A (ja) 2017-05-18
BR112016020368A2 (pt) 2018-01-23
US11352414B2 (en) 2022-06-07
SG11201606597QA (en) 2016-09-29
US20170088603A1 (en) 2017-03-30
RU2016139006A (ru) 2018-04-05
AU2015226100A1 (en) 2016-08-25
EP3114143A1 (en) 2017-01-11
EP3114143B1 (en) 2020-07-08
JP6851200B2 (ja) 2021-03-31
TW201619188A (zh) 2016-06-01
CA2939198A1 (en) 2015-09-11
IL247096A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
MX2016010951A (es) Proteinas de fc multimericas.
MX2016010953A (es) Proteinas de fc multimericas.
BR112016023948A2 (pt) proteínas fc multiméricas
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
PL3865506T3 (pl) Białko fuzyjne do zastosowania w leczeniu choroby hvg
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX393740B (es) Anticuerpos contra alfa-sinucleina y sus usos.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2015015249A (es) Peptidos terapeuticos.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
PL3348273T3 (pl) Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych
NZ728662A (en) A process for purification of rhu-gcsf
IL247481A0 (en) tatk-cdkl5 fusion proteins, preparations, formulations, and their uses
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.